Dengue Virus Inhibitors as Potential Broad-Spectrum Flavivirus Inhibitors

Area of Science:

• Virology
• Drug Discovery
• Molecular Biology

Background:

• Flaviviruses pose a global health threat due to their widespread transmission and lack of effective treatments.
• The emergence of flaviviral diseases necessitates the development of novel antiviral therapies.
• Identifying broad-spectrum inhibitors is crucial for combating diverse flaviviral infections.

Purpose of the Study:

• To evaluate previously identified Dengue virus (DENV) inhibitors for activity against other flaviviruses.
• To discover potential broad-spectrum antiviral agents for flaviviral infections.
• To investigate the anti-TBEV activity of specific compounds.

Main Methods:

• Cytotoxicity assays (WST-1) to determine compound safety.
• Inhibition assays against Dengue virus 2 (DENV2), Zika virus (ZIKV), Kunjin virus (KUNV), and Tick-borne encephalitis virus (TBEV).
• Replicon-based assays and molecular dynamics simulations for active compounds.

Main Results:

• Two of eight DENV2/DENV4 inhibitors showed broad-spectrum activity against all tested flaviviruses at low micromolar concentrations.
• Compound C6 inhibited both DENV2 and TBEV.
• Lycorine (C1), mycophenolic acid (C3), and vidarabine (C7) were identified as novel TBEV inhibitors.

Conclusions:

• Compounds effective against DENV can also inhibit other flaviviruses, highlighting potential broad-spectrum applications.
• This study provides the first report of anti-TBEV activity for lycorine, mycophenolic acid, and vidarabine.
• Experimental validation is essential, as demonstrated by the confirmation of C5's antiviral activity and C8's lack thereof.